An accelerated design, combined, prospective ascending single-dose and two-dose, randomised, placebo-controlled, blinded, first-in-human adaptive study in healthy adults and patients with COVID-19 infection, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody AOD01

  • Funded by National Medical Research Council Singapore
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    National Medical Research Council Singapore
  • Principal Investigator

    A/Prof. Chien and David Boon and Lye
  • Research Location

    Singapore
  • Lead Research Institution

    NCID (TTSH)
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract